Curcumin is Key to Unlocking Cancer Epigenetic Code - EuroPharma. PRNewswire GREEN BAY, Wis., June 23, 2011 /PRNewswire/ -- Dr.
Ajay Goel, Ph.D., Director of Epigenetics and Cancer Prevention at the Gastrointestinal Research Center at Baylor University Medical Center in Dallas, TX, has announced plans for a series of upcoming studies to continue to unlock the mechanisms by which curcumin prevents cancer via its influence on epigenetic activity. While many people believe there is a strong genetic influence in the development of cancer, Dr. Goel states this is untrue.
"Less that 5% of cancers arise from broken or damaged genes. In a study published in the journal Gastroenterology, entitled "Novel Evidence for Curcumin-induced DNA Methylation Changes in Colon Cancer Cells,"(1) Dr. "It was a very technical study," reports Dr. BCM-95(R) curcumin was used in this study. EuroPharma, Inc. is the exclusive distributor of BCM-95(R) curcumin products in the U.S. through both the health food store and professional distribution channels. . (1) A. EuroPharma, Inc. Curcumin awakens sleeping genes and reignites tumor suppression activity… A few days ago, I got very excited about the announcement of a newly released study: “Research at Baylor University shows curcumin awakens sleeping genes and reignites tumor suppression activity.”
Holy crackers! Here is the link: Is There Any Other Anti-Cancer Botanical Compound As Exciting As Curcumin? - Integrative Oncology Essentials. Curcumin Modulates DNA Methylation in Colorectal Cancer Cells. Aim Recent evidence suggests that several dietary polyphenols may exert their chemopreventive effect through epigenetic modifications.
Curcumin is one of the most widely studied dietary chemopreventive agents for colon cancer prevention, however, its effects on epigenetic alterations, particularly DNA methylation, remain unclear. Using systematic genome-wide approaches, we aimed to elucidate the effect of curcumin on DNA methylation alterations in colorectal cancer cells. Materials and Methods To evaluate the effect of curcumin on DNA methylation, three CRC cell lines, HCT116, HT29 and RKO, were treated with curcumin. 5-aza-2′-deoxycytidine (5-aza-CdR) and trichostatin A treated cells were used as positive and negative controls for DNA methylation changes, respectively.
Results Conclusions. Digging for Answers: The Potential of Curcumin as an Epigenetic Therapeutic Drug to Treat Cancer. The brilliant golden powder of turmeric is best known as the main spice in curry, but has also been widely used for many years in Eastern traditional medicines as an anti-inflammatory agent.
Turmeric has been used as an alleviator for arthritis, stomach pain, and cancer, among many other health issues. The healing properties of turmeric are attributed to curcumin, a polyphenol that is naturally derived from an underground portion of the turmeric plant. While hundreds of studies have examined curcumin as an anticancer and chemopreventive compound, only recently have research groups investigated the effect of curcumin on epigenetic processes. Data in a paper published earlier this year suggest that curcumin influences DNA methylation patterns in a certain subset of genes within colorectal cancer (CRC) cells, and that these changes frequently correspond with changes in gene expression. Link A, Balaguer F, Shen Y, Lozano JJ, Leung HC, Boland CR, & Goel A (2013). Development of curcumin as an epigenetic agent. [Cancer. 2010. Epigenetic changes induced by curcumin and other natural compounds. Development of curcumin as an epigenetic agent - Fu - 2010 - Cancer.
Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis - Prakobwong - 2010 - International Journal of Cancer. Abstract Cholangiocarcinoma (CCA) is a highly metastatic tumor linked to liver fluke infection and consumption of nitrosamine-contaminated foods and is a major health problem especially in South-Eastern Asia.
In search for a suitable chemopreventive agents, we investigated the effect of curcumin, a traditional anti-inflammatory agent derived from turmeric (Curcuma longa), on CCA development in an animal model by infection with the liver fluke Opisthorchis viverrini and administration of N-nitrosodimethylamine and fed with curcumin-supplemented diet. The effect of curcumin-supplemented diet on histopathological changes and survival were assessed in relation to NF-κB activation, and the expression of NF-κB-related gene products involved in inflammation, DNA damage, apoptosis, cell proliferation, angiogenesis and metastasis. Our results showed that dietary administration of this nutraceutical significantly reduced the incidence of CCA and increased the survival of animals.
Discussion. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. + Author Affiliations ↵*To whom correspondence should be addressed.
Tel: +66 43 348 387; Fax: +66 43 202 475; Email: email@example.com Correspondence may also be addressed to Bharat B.Aggarwal. Tel: +66 713 794 1817; Fax: +66 713 745 6339; Email: firstname.lastname@example.org Received December 16, 2010. Revision received January 22, 2011. Accepted February 6, 2011. Abstract Cholangiocarcinoma (CCA) is a tumor with poor prognosis that is resistant to all currently available treatments. Introduction Cholangiocarcinoma (CCA) is a highly malignant, generally fatal adenocarcinoma arising from the bile duct epithelial cells (cholangiocytes) of the intrahepatic or extrahepatic biliary system.
Chronic inflammation has been shown as a link between CCA and its risk factors (1). Natural products have played a significant role over the years in the development of anticancer drugs as>60% of the drugs are of natural origin (20,21). Materials and methods Materials Fig. 1. Cell lines Clonogenic assay Results. Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment.